title: Impact of medication therapy management in patients with Parkinson's disease.
abstract: BACKGROUND
  Since the new German Apothekenbetriebsordnung was released, medication therapy management (MTM) has increased in importance. MTM is intended to improve the quality of life of patients.
  
  
  OBJECTIVE
  The aim of this study was to improve the quality of life of patients with Parkinson's disease through an MTM by a community pharmacist.
  
  
  METHODS
  The patients were recruited in cooperation with the Deutsche Parkinson Vereinigung e.V. (dPV) in Germany. Methods All patients were evaluated at baseline (t0) and after a follow-up of 4 months (t1). During the intervention period, the pharmacists implemented an MTM with standardized pharmaceutical care. Main outcome measure The effects of the interventions were measured by the Unified Parkinson Disease Rating Scale (UPDRS) and the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS).
  
  
  RESULTS
  In this study, 90 patients with Parkinson's disease were included. The most common intervention was to find a therapy for untreated comorbidities. The UPDRS or MDS-UPDRS improved significantly after the intervention period by a median change rate of 1 (p < 0.05) or rather 2 (p < 0.05) compared to the baseline.
  
  
  CONCLUSIONS
  The study shows that the quality of life in Parkinson's disease patients improved significantly through MTM.
authors.affiliation: Institute of Pharmaceutical and Medical Chemistry, Westfälische Wilhelms-University Münster, Corrensstraße 48, 48149, Münster, Germany. martina.henrichsmann@gmx.de.
authors.forename: Martina
authors.initials: M
authors.lastname: Henrichsmann
authors.affiliation: Institute of Pharmaceutical and Medical Chemistry, Westfälische Wilhelms-University Münster, Corrensstraße 48, 48149, Münster, Germany.
authors.forename: Georg
authors.initials: G
authors.lastname: Hempel
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003157:Community Pharmacy Services / Q000592:standards; D015897:Comorbidity; D019091:Critical Pathways; D016208:Databases, Factual; D005260:Female; D005858:Germany; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D054539:Medication Therapy Management / Q000592:standards; D008875:Middle Aged; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D017064:Process Assessment, Health Care; D058996:Quality Improvement; D019984:Quality Indicators, Health Care; D011788:Quality of Life; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents
keywords: Community pharmacist; Germany; Medication therapy management; Parkinson’s disease; Pharmaceutical care